RxDoctor Payments Data

Annabelle Pannell

Nurse Practitioner · Clintwood, VANPI 1316246242

Payments from drug & device makers

$3,099in general payments, 2019–2025

Across 192 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$719
  • Novo Nordisk$494
  • AstraZeneca$404
  • Pfizer$245
  • Vanda Pharmaceuticals Inc.$224
  • Lilly USA, LLC$135
  • plus $879 from 24 others

What the payments were for

  • Food & beverage$3,099100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,099 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$2,271
Medicare patients
48
Services billed
77

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$57,763
EliquisApixaban93$55,578
FarxigaDapagliflozin Propanediol52$45,578
TrulicityDulaglutide19$28,597
JardianceEmpagliflozin16$22,253
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$18,284
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$13,380
MounjaroTirzepatide11$11,762
LinzessLinaclotide15$9,868
XareltoRivaroxaban12$7,950
SymbicortBudesonide/Formoterol Fumarate15$3,403
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,687
Albuterol Sulfate HfaAlbuterol Sulfate96$1,820
Famotidine84$1,708
Atorvastatin Calcium163$1,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$404$67,26695 claims
Novo NordiskOzempic$494$57,76353 claims
PfizerEliquis$245$55,57893 claims
Lilly USA, LLCTrulicity, Mounjaro$135$40,35930 claims
AbbVieLinzess, Synthroid$719$10,43228 claims
Johnson & JohnsonXarelto$46$7,95012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Clintwood

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →